Rate of initial highly active anti-retroviral therapy regimen change and its predictors among adult HIV patients at University of Gondar Referral Hospital, Northwest Ethiopia: a retrospective follow up study by Degefaye Zelalem Anlay et al.
Anlay et al. AIDS Res Ther  (2016) 13:10 
DOI 10.1186/s12981-016-0095-x
RESEARCH
Rate of initial highly active anti-retroviral 
therapy regimen change and its predictors 
among adult HIV patients at University 
of Gondar Referral Hospital, Northwest Ethiopia: 
a retrospective follow up study
Degefaye Zelalem Anlay1*, Zinahbizu Abay Alemayehu2 and Berihun Assefa Dachew3
Abstract 
Background: Regimen change is a major challenge for the sustainability of human immunodeficiency virus (HIV) 
treatment program. In a resource limited setting where treatment options are limited, designing strategies to increase 
the durability of original regimen are essential. However, information’s on rate of initial regimen change and its predic-
tors is scarce in Ethiopia. Therefore, the purpose of this study was to assess the rate of initial highly active anti retroviral 
therapy (HAART) regimen change and its predictors among adult HIV patients at the University of Gondar Referral 
Hospital, Northwest Ethiopia.
Methods: An institutional based retrospective follow up study was conducted among 410 adult HIV patients started 
HAART from January 2010 to December 2014. Simple random sampling technique was used to select patient records 
using computer generated random number. Data were collected from patient chart using data extraction tool. The 
Kaplan–Meier curve was used to estimate the median duration of regimen change. Life table was used to estimate 
the cumulative survival for initial regimen change and log rank test to compare regimen change survival curves 
between the different categories of explanatory variables. Bivariate and multivariate Cox proportional hazard model 
were used to identify predictors of initial regimen change.
Results: The overall incidence rate of initial regimen change was 10.11 (95 % CI 8.29, 12.6) per 100 person years (PY). 
Baseline WHO clinical stage III (AHR = 1.92, 95 % CI 1.12–3.35), occurrence of tuberculosis (TB) on the initial regimen 
(AHR = 8.33, 95 % CI 4.47–15.53), side effect on the initial regimen (AHR = 25.27, 95 % CI 15.12–42.00) and co-medica-
tion with ART (AHR = 2.5, 95 % CI 1.46–4.34) were significant predictors of initial regimen change.
Conclusions: The rate of initial HAART regimen change was found to be high. Having WHO clinical stage III, co-
medication with ART, occurrence of tuberculosis and side effect on initial regimen were independent predictors of 
regimen change. Hence, close follow-up and screening of patient for side effect and tuberculosis is important.
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Background
The survival of HIV patient increased due to the scale up 
of antiretroviral therapy and changed HIV infection into 
chronic conditions. However, changes in treatment and 
poor adherence limit the therapeutic success of original 
regimen and sustainability of HIV treatment program 
since antiretroviral therapy is a lifelong therapy. As far 
as there is virological success, the initial regimen contin-
ues unless the need of regimen changes due to drug side 
effect, co-morbid illness, pregnancy and other conditions 
[1–3].
Improving the long term access and sustainability of 
HIV treatment program by optimizing the limited avail-
able combined anti-retroviral regimen is vital. Succes-
sive regimens are inferior to that of the original regimen 
in related to effectiveness and duration. In addition to 
this; regimen change result in a number of challenges, 
reduce both the duration and the chance of viral control 
due to cross resistance between different alternative drug 
and overlapping toxicity between and within a class of 
antiretroviral (ARV) drug. Subsequently, the likelihood 
that successful HAART will last life time is poor [1, 2, 4, 
5]. Besides, second line ART is more expensive than that 
of first line HAART [6].
A multi-center study in North America and Europe 
showed that the incidence of regimen change were 
14.4/100 person years (PY) [7]. Furthermore, 13.8/100PY 
in Thailand [8], 41.5/100PY in Swiss [9], 28.3/100PY in 
Brazil [10], 16.2/100PY in West Africa [11], 18.6/100PY 
in Kenya [12] and the proportion of regimen change in 
Ethiopia was 21.8 % [13]. Different studies revealed that 
baseline regimen [1, 12, 14], WHO stage [12, 15], CD4 
count [6, 16, 17] and patient weight [12, 15] were some 
predictors of initial regimen change.
In resource limited setting including Ethiopia where 
treatment options are limited; designing strategies to 
increase the durability of original regimen is essential. So 
as to achieve this goal, it is important to determine the 
rate and predictors of initial HAART regimen change. 
However, information’s on rate of initial HAART regi-
men change and its predictor in Ethiopia is scarce. There-
fore, this study was aimed to determine the rate of initial 
HAART regimen change and its predictor among adult 
HIV patients. Results from this study will help to design 
appropriate measures to increase the duration of origi-
nal regimen among patients on antiretroviral therapy 




Institution based retrospective follow up study was con-
ducted to determine the rate of initial HAART regimen 
change and it’s predictor among adult HIV patients at 
University of Gondar Referral Hospital, North West Ethi-
opia, from January 2010 to June 2015. The study was con-
ducted at Gondar University Hospital ART clinic from 
May 25 to June 10 2015. University of Gondar Referral 
Hospital is a teaching Hospital which serves more than 
five million people of the North Gondar zone and peo-
ples from the neighboring zones. The HIV care service of 
the Hospital was initiated in 2005 and has 7 outpatient 
rooms, one voluntary testing and counseling room, one 
pharmacy, and one laboratory. Since 2005 in which the 
hospital started ART, 7581 adults and 738 pediatrics 
patients are enrolled to the HIV care. Currently 4891 
adults are actively following their treatment.
Standardized monitoring and evaluation tool and the 
data collection and management process are well organ-
ized and supported by electronic data base system of the 
hospital. During the study period, based on Ethiopian 
FMOH update for ART initiation criteria for adult and 
adolescent patients, the ART initiation criteria were either 
the CD4 count 350 cell/mm3 or when WHO stage III and 
IV disease. The choice of ART drug is based on baseline 
clinical (history and physical examination) and laboratory 
results (HGB, Liver function test, renal function test). The 
first line regimen consisted of NRTI backbone zidovudine 
(AZT) or Stavudine (d4T) or Tenofovir (TDF) or Abacavir 
(ABC) with Lamivudine (3TC) and either Efavirenz 
(EFV) or Nevirapine (NVP). Of which the preferred first 
line drug is TDF-3TC-EFV and the alternative first line 
regimen are ZDV+3TC+EFV, ZDV+3TC+NVP and 
TDF-3TC-EFV. After initiation of therapy the patient is 
appointed at 2 weeks, at 1 month, and every month for the 
first 6 months and then after ever 3 months. Monitoring 
is done through CD4 count at baseline, every 6  months 
but only for exceptional case viral load is done specially to 
assure treatment failure suspected case.
Definition of initial regimen change
Initial regimen change defined as, a switch or substitu-
tion of at least one drug from the original HAART regi-
men. Regimen change, which is defined in this study, as an 
event, through the follow up period was ascertained retro-
spectively when the patients is recorded as changed their 
regimen and start other HAART drug. According to 2008 
Ethiopian federal ministry of health ART guideline which 
was adopted from WHO guideline; the reasons for treat-
ment change were based on the occurrence toxicity (grade 
III and IV), tuberculosis, pregnancy, treatment failure and 
others. Treatment failure was defined as immunological fail-
ure (fall of CD4 count to pre-Rx baseline or below or 50 % 
fall from the on-treatment peak value or persistent CD4 lev-
els below 100 cells/mm3), clinical failure (new or recurrent 
WHO stage 4 condition) or virological failure (plasma VL 
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above 10,000 c/ml for study period). Patients with the first 
date of lost to follow up, transfer out, death before the end 
of the follow up period and completed the follow up period 
without developed the event were considered as censored.
Inclusion criteria
All patients aged 15 and above who were started HAART 
at University of Gondar Hospital, from 1st January 2010 
to 31st December 2014. Within this period a total of 2521 
and out of whom 410 patients record were reviewed.
Sample size and sampling technique
The sample size was determined by using single popula-
tion proportion formula through EPI INFO Stat Calc pro-
gram with the assumption of 95 % level of confidence, 4 % 
of marginal error, and taking prevalence of regimen change 
21.8 % [18]. With this consideration the final sample size 
became 410. Patient’s chart numbers were taken from the 
electronic data base as a sampling frame. From a total of 
2521 patients who were started HAART 410 charts were 
selected and reviewed by simple random sampling tech-
nique through computer generated random number.
Data collection tools and procedures
The available information on the patient records had 
been first observed and appropriate data extraction for-
mat was prepared in English. Then the data were col-
lected by four nurses who had ART training using the 
prepared data collection format on the already existing 
records after half day theoretical and half day practical 
training given. One data clerk also supported them by 
identifying the charts. Charts were retrieved using the 
patient registration number which was found in the data 
base in the electronic system.
Data quality control
Quality of data was maintained by recruiting data col-
lectors who had taken ART training. The data collectors 
were given intensive training for one day before the data 
collection about the objective of the study and how to 
retrieve data for this study purpose using the data extrac-
tion format. They briefed on the definition of variables 
on the questionnaires and registration charts. The data 
extraction tool was pre-tested for consistency of under-
standing the review tools, and completeness of data items 
on 21 charts at the same facility as it was a secondary 
data and the necessary amendment were made on the 
final data extraction format. The retrieval process was 
closely monitored by the principal investigator through-
out the data collection period. Completed questionnaires 
were checked regularly for completeness of information 
and any gaps identified were immediately communicated 
to the data collectors.
Data processing and analysis
After the data were checked for its consistency and com-
pleteness, it was entered to EPI-INFO version 7.0 then 
exported to SPSS version 20 for cleaning and analysis. 
Summary statistics were carried out to describe the demo-
graphics, baseline and follow up data. Incidence density 
rate (IDR) was calculated for the entire study period. To 
calculate rate of regimen change among peoples on ART, 
the total duration of follow up for the whole cohort in per-
son year (PY) was used. The follow up duration for peoples 
on ART who did not change their regimen was calculated 
from the time of initiation of ART until the last visit. For 
those who are changing their regimen; the follow up dura-
tion was calculated from initiation of HAART to a sub-
stitution of at least one drug from the original regimen. 
Subsequently, the number of cases who changes their regi-
men within the cohort was divided by the total regimen 
change free follow up duration and reported per 100PY.
The survival analysis technique was carried out, as 
this study has considered time-to-event data, Cox pro-
portional hazard model was fitted, and a life table was 
used to estimate cumulative probabilities. The Kaplan–
Meier curve was used to estimate the median duration 
of regimen change. Log rank test was used to compare 
survival curves between the different categories of the 
explanatory variables. Both bivariate and multivariate 
Cox proportional hazard model were used to identify the 
predictors. Variables with p value  <0.2 in the bivariate 
analysis were entered into the multivariate proportional 
hazard model. 95 % CI of hazard ratio was computed and 
variable having p value <0.05 in the multivariate Cox pro-
portional hazards model was considered as significantly 
and independently associated with the dependent vari-
able. Cox proportional hazard model fitness was checked 
using schoenfield residual test.
Ethical statement
Ethical clearance was obtained from the Institutional 
Review Board (IRB) of the University of Gondar. Permis-
sion letter was obtained from the clinical director of the 
Hospital. The HIV care clinic head gave the consent for 
extracting data from records. The confidentiality of the 
patient was ensured by avoiding name and identification 
number from extracting.
Results
Socio‑demographic, baseline clinical and immunological 
status of the respondents
Four hundred ten records were analyzed. The mean 
age at the initiation of ART was 33.3  ±  8.7  years and 
181 (44.1  %) of the participant were in the age group 
between 25 and 34 years. More than half of the respond-
ents 265 (64.6 %) were female and majority 363 (88.5 %) 
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of them were Orthodox Christian. Regarding the level 
of education 123 (30  %) of the respondents were com-
pleted secondary education. The majority 337 (82.2  %) 
of the respondents were urban dwellers. A total of 372 
(90.7 %) patients had disclosed their HIV status to either 
their family or other relatives. Three hundred fifty nine 
(87.6 %) did not use any type substance (Table 1).
The majority of the participants, 376 (91.7 %) were eli-
gible to HAART by CD4 count of which 56 (13.6 %) were 
also eligible clinically. The mean weight of the Participant 
was 53.58 ± 9.55 kg. The predominant HAART regimen 
initially prescribed for them were a combination of zido-
vudine, Lamivudine and Nevirapine (AZT-3TC-NVP), 
177 (43.2 %) followed by Tenofovir, Lamivudine and Efa-
virenz (TDF-3TC-EFV) for 147 (35.9 %) cases.
More than half 221 (53.9  %) of participants, were initi-
ated on NVP based regimen. Nearly half 201 (49 %) of the 
patients were started by taking two ART pills/day and 401 
(97.8  %) of the participant were taking CPT prophylaxis. 
One hundred seventy two (42 %) were WHO clinical stage 
III at the initiation of HAART. The majority, 361 (88 %) of 
the participant were on working functional status at a base-
line. The median CD4 count at initiation of HAART and the 
end of follow up was 162.5 [IQR 90.5–235.5] and 291 [IQR 
170–433] respectively. Nearly half, 192 (46.8  %) of study 
subjects were started HAART at HGB level of ≥  13  g/dl. 
One hundred fifteen (28 %) of the study participants were 
diagnosed for opportunistic infection before initiation of 
HAART and after confirmation of HIV infection (Table 2).
Rate of regimen change
Four hundred ten study subjects who were followed for 
different period gave a total of 10436.2 person months 
(869.68 person years) of observation. Within a follow up 
period, a total of 88 (21.5 %) of patients were changed their 
initial regimen. This makes the overall rate of initial regi-
men change 10.11/100 PY (95 % CI 8.29, 12.6 PY). Regard-
ing to the time of initial regimen change, 53 (60.2  %), 63 
(71.6 %) and 80 (90.9 %) were changed their regimen within 
6 months, 1 year and 3 years respectively, the remaining 8 
(9.1 %) were changed after 3 years of follow up. The cumu-
lative probability of surviving on initial regimen at the end 
of 6 months was 0.83; at the end of 1 years 0.81; at the end 
of 3  years 0.73 and the end of follow up was 0.7 (Fig.  1). 
Among the reasons for regimen change, side effect was 
the commonest reason which accounts for 62 (70.45 %) of 
cases and contribute for the 7.13/100PY. Tuberculosis 18 
(20.45 %), pregnancy 4 (4.5 %), virological failure 3 (3.4 %) 
and occurrence of hepatitis B with chronic liver diseases 1 
(1.14 %) were other reasons for regimen change. The com-
monest side effect for regimen change was found to be ane-
mia 33 (53.2 %), followed by rash 14 (22.6 %) (Table 3).
Predictor of regimen change
In the multivariate Cox-regression analysis, baseline 
WHO clinical stage, co-medication with ART, occur-
rence of TB and side effect on initial regimen remained 
a significant predictor of the initial regimen change. 
Accordingly, HIV patients who were stage III at initiation 
of HAART increased the risk of initial regimen change by 
1.92 times when compared to those who were stage I/II 
at any time (AHR = 1.92, 95 % CI 1.12,3.35). Those who 
Table 1 Baseline socio demographic characteristics 
of HIV positive adults at  initiation of HAART at University 
of  Gondar Referral Hospital, January 2010 to  December 
2014 (n = 410)
Characteristics Frequency Percentage (%)
Age
 15–24 51 12.4
 25–34 181 44.1
 35–44 126 30.7
 ≥ 45 52 12.7
Sex
 Female 265 64.6
 Male 145 35.4
Marital status
 Married 186 45.4
 Divorced 96 23.4
 Single 73 17.8
 Widowed 31 7.6
 Separated 24 5.9
Religion
 Orthodox 363 88.5
 Muslim 39 9.5
 Protestant 6 1.5
 Catholic and Jewish 2 0.4
Level of educational
 Not educated 127 31
 Primary 102 24.9
 Secondary 123 30
 Tertiary 58 14.1
Occupation
 Unemployed 326 79.52
 Employed 84 20.48
Residence
 Urban 337 82.2
 Rural 73 17.8
Disclosure status
 Disclosed 372 90.7
 Not disclosed 38 9.3
Substance use
 No 359 87.6
 Yes 51 12.4
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were developed TB on an initial regimen had about 8.33 
times at higher risk of changing their initial regimen at 
any time as compared to those who did not develop TB 
(AHR = 8.33, 95 % CI 4.47, 15.53) (Fig. 2).
Patients on HAART who were taking other medication 
with ART had about 2.54 times at higher risk of chang-
ing their initial regimen at any time as compared to those 
who did not take other medication (AHR = 2.5, 95 % CI 
1.46, 4.39). Those who had ART drug side effect on ini-
tial regimen were 25.27 times at higher risk of changing 
their initial regimen as compared to those who had not 
side effect (AHR = 25.27, 95 % CI 15.12–42.00) (Table 4).
Discussion
The rate of initial regimen change among adult HIV 
patients on HAART was found to be 10.11/100PY (95 % 
CI 8.29, 12.6 PY). This finding is lower than a study 
Table 2 Baseline clinical and  immunological status 
of  HIV positive adults at  initiation of  HAART, University 




 AZT-3TC-NVP 177 43.2
 TDF-3TC-EFV 147 35.9
 AZT-3TC-EFV 37 9
 TDF-3TC-NVP 28 6.8
 D4T(30)-3TC-NVP 16 3.9
 D4T(30)-3TC-EFV 3 0.7
 ABC-3TC-EFV 2 0.5
Number of ART pill/day
 One 128 31.2
 Two 201 49
 Three 40 9.8
 Four 41 10
CPT prophylaxis
 Yes 401 97.8
 No 9 2.2
Past OI before HARRT initiation
 No 295 72
 Yes 115 28
Functional status
 Working 361 88
 Ambulatory 29 7.1
 Bed ridden 20 4.9
WHO clinical stage
 I 105 25.6
 II 73 17.8
 III 172 42
 IV 60 14.6
CD4 count
 <100 cell/mm3 110 26.8
 100–199 cell/mm3 150 36.6
 200–349 cell/mm3 133 32.4
 ≥350 cell/mm3 17 4.1
Baseline Hgb
 <7 g/dl 8 2
 7–9.9 g/dl 37 9
 10–12.9 g/dl 173 42.2
 ≥13 g/dl 192 46.8
Base line weight
 <60 kg 318 77.6
 ≥60 kg 92 22.4
Fig. 1 Kaplan-Meir curve of surviving on initial regimen proportion 
for HIV positive adults on initial HAART at University of Gondar referral 
Hospitals, starting ART from January 1 2010 to June 2015)
Table 3 Common side effects among  patients with  regi-
men change at  University of  Gondar Referral Hospital 
from January 2010 to June 2015 (n = 88)
Types of side effect Frequency Percent
Anemia 33 53.22
Rash 14 22.58
Peripheral neuropathy 9 14.51
Nausea and vomiting 5 8.06
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conducted in Thailand 13.8/100PY [8], multicenter study 
in North America and Europe 14.4/100PY [7], Brazil 
28.3/100PY [10] and Swiss 41.5/100PY [9]. This might 
be explained by the difference in defining outcome vari-
ables, since in our case we did not considered treatment 
discontinuation as regimen change unless they restart 
with different regimen. Furthermore, limited combined 
antiretroviral options or WHO based guideline in our 
setting may limit the clinician decision on cART modifi-
cation. The other possible reasons might be regular mon-
itoring of viral load for treatment response in developed 
countries might pick virological failure earlier which calls 
the need for regimen change.
Similarly, it is lower than studies done in West Africa 
and Kenya with a rate of 16.2/100PY and 18.6/100PY 
respectively [11, 12]. This might be due to the differ-
ence in follow up period 15 and 10.7  months in West 
Africa and Kenyan study but 23.28  months for our 
study. In addition to this our study include participants 
who started HAART after 2010 in which WHO recom-
mended to phase out D4T but West Africa and Kenyan 
studies were done before 2011 which might overestimate 
the rate.
In this study, being in WHO clinical stage III at ini-
tiation of ART, occurrence of TB on initial regimen, co-
medication with ART and side effect on initial regimen 
were found to be predictors of regimen change.
Those who had started HAART at baseline WHO 
clinical stage III were nearly two times at higher risk of 
changing their initial regimen as compared to those with 
WHO clinical stage I/II. This finding is in line with stud-
ies done in Switzerland and two Kenyan studies [12, 15, 
16]. This might be due to the fact that those patients who 
had advanced disease are likely to be on other medica-
tions which might result in drug interaction, side effect 
which in turns result in drug change. In contrary with 
other most studies, in this study WHO clinical stage IV 
were not a predictors for initial regimen change. The pos-
sible reason might be, low survival of patient on stage 
four which may result in death before the occurrence of 
the event.
Those who had co-medication with HAART were 
nearly two and half times increase the hazard of chang-
ing their initial regimen at any time as compared to those 
who did not take other medication. This is supported by 
Swiss HIV cohort and Ethiopian study at Mekelle hos-
pital [9, 18]. The possible reason might be drug—drug 
interaction and overlapping toxicity between ART drugs 
and other medication. The other possible explanation 
Fig. 2 Kaplan-Meier curve of surviving on initial regimen proportion 
based on the occurrence of tuberculosis on initial regimen in Univer-
sity of Gondar Referral Hospital from January 2010 to June 2015
Table 4 Bivariate and  multivariable Cox regression 
analysis for  predictors of  initial HAART regimen change 
among adult HIV positive patients at University of Gondar 
Referral Hospital, January 2010 to June, 2015 (n = 410)
* Statistically significant at p value <0.05
Variable Survival status Crude HR  
(95 % CI)




 <60 kg 56 262 1.00 1.00




23 155 1.00 1.00
 Stage III 50 122 2.45 (1.49–4.01) 1.92 (1.12–3.31)*
 Stage IV 15 43 1.945 (1.01–3.73) 0.55 (0.25–1.18)
TB on initial regimen
 Yes 20 6 7.92 (4.76–13.16) 8.33 (4.47–15.53)*




26 151 1.00 1.00
 AZT/
D4T
62 171 1.68 (1.06–2.65) 072 (0.40–1.28)
Initial NNRTI
 NVP 60 161 1.84 (1.17–2.88) 1.74 (0.79–3.84)
 EFV 28 161 1.00 1.00
Co-medication with ART other than CPT
 Yes 32 52 2.68 (1.74–4.15) 2.54 (1.46–4.39)*
 No 56 270 1.00 1.00
Side effect
 Yes 63 9 18.93 (11.82–30.29) 25.27 (15.12–42)*
 No 25 313 1.00 1.00
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might be poly pharmacy which could lead to poor adher-
ence due to pill burden which in turn resulted in poor 
efficacy of treatment result in drug change secondary to 
treatment failure.
Those who had side effect on the initial regimen were 
nearly twenty five times increased the hazard of chang-
ing their initial regimen at any given time as compared to 
those who did not develop side effect. This finding is sup-
ported by studies done in India, Nigeria and Ethiopia [14, 
18, 19]. This is due to the fact that the occurrence of side 
effect alter the quality of life and even result in a death 
of a patient and it is a short term predictor for regimen 
change specially for grade III and IV toxicity but WHO 
recommend to follow the side effect cautiously for grade I 
and II toxicity before regimen change [5].
Those who had developed TB on initial regimen were 
nearly eight times at higher risk of changing their ini-
tial regimen at any time as compared to those who did 
not develop TB. This study is supported with a study 
done in India [19] and another literatures put it as one 
of the major reasons for regimen change [2, 12, 15]. In 
fact, tuberculosis is one of the opportunistic infection 
that occurs at any CD4 count in HIV patient, it might 
predicts clinical failure if it occurs after 6 months of ini-
tiation of ART which subsequently indicate the need of 
treatment change [11]. The other reason is the enzyme 
inducer nature of TB drugs specially Rifampicin induces 
cytochrome 450 enzyme that facilitate the metabolic 
activity of liver which makes under therapeutic level of 
ART drugs specially NVP which result in viral resist-
ance, this calls for the need of regimen change when TB 
develop [5].The other explanation might be the pill bur-
den result in poor adherence and its common toxicity 
with ART drugs result in the need for change [20].
Because of the retrospective nature of the study some 
important predictors which had a significant association 
with initial regimen change in other studies, like BMI and 
hepatitis B and C infection were missed.
Conclusions
Rate of initial regimen change was found to be high and 
most of the change occurred within a year after initiation 
of HAART. Having WHO clinical stage III at initiation 
of ART, occurrence of TB on initial regimen, co-medica-
tion with ART and side effect up on initial regimen were 
found to be predictors of regimen change. Therefore, it 
is important to give special attention for patients who 
have advanced disease and taking additional medication. 
Strengthening care full follows up and screening for side 
effect and tuberculosis is important.
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